Demonstration of anti-inflammatory properties of an inhaled p38 inhibitor AZD7624 Source: International Congress 2015 – Therapeutic approaches in inflammatory lung disease Year: 2015
The effect of in vitro culture methods on corticosteroid sensitivity in COPD alveolar macrophages Source: Annual Congress 2013 –COPD: experimental biology Year: 2013
AZD7624, an inhaled p38 inhibitor for COPD, attenuates lung and systemic inflammation after LPS Challenge in humans Source: International Congress 2015 – Advances in the future treatment of COPD Year: 2015
Effect of p38 MAPK inhibition on corticosteroid suppression of cytokine release in severe asthma Source: Eur Respir J 2010; 35: 750-756 Year: 2010
Simvastatin suppresses the activity of Th2 and Tc2 cells in atopic asthma and in COPD Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
Repeated lipopolysaccharide stimulation causes corticosteroid insensitive inflammation in lung via phosphoinositide-3-kinase δ signaling Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
The anti-inflammatory effects of sulforaphane are not mediated by the Nrf2 pathway Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014
The effect of the novel SHIP1 activator AQX-1125 on allergen-induced responses in mild to moderate asthma Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013
Inhibition of p38 mitogen-activated protein kinase has no effect on macrophage phagocytosis of bacteria in patients with COPD Source: Annual Congress 2013 –Macrophages, mononuclear cells and viral infection Year: 2013
Differential anti-inflammatory effects of budesonide and a p38 MAPK inhibitor AZD7624 on COPD pulmonary cells Source: International Congress 2018 – Preclinical pharmacology: novel targets in airway inflammation, narrowing and neural control Year: 2018
Aerobic exercise reduces asthma phenotype by inhibition of JAK2, SOCS3 and STAT6 in airway epithelium and in peribronchial leukocytes Source: International Congress 2016 – Latest insights into functional capacity and muscle weakness in chronic lung diseases Year: 2016
Systemic inhibition of p38 MAPK improves lung function and inflammatory markers in moderate-severe COPD Source: International Congress 2015 – New data on established treatments for COPD Year: 2015
Novel, highly potent and selective JAK3 inhibitor disrupting IL-4/IL-13 signaling in asthma therapy Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015
cPLA2alpha inhibitor ASB14780 suppresses airway MMP-9 production and improves respiratory function in cigarette-smoke induced model Source: International Congress 2014 – Animal models in respiratory drug development Year: 2014
Increased expression of sphingosine-1-phosphate and S1PR2 are associated with attenuated macrophage phagocytosis in COPD Source: Annual Congress 2013 –COPD: experimental biology Year: 2013
Additive anti-inflammatory effect of glucocorticoids and PDE4 inhibitors on COPD CD8 cells Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
RP6503, a novel and selective PI3K δ/gamma inhibitor, potentiates the effect of steroids in pre-clinical models of COPD Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
The effect of the inhaled PDE4 inhibitor CHF6001 on allergen-induced inflammation in asthmatics Source: International Congress 2014 – Asthma and COPD management Year: 2014
Maintenance of IRF1 by MAPK inhibition: A mechanism by which DUSP1 reduces glucocorticoid inhibition of CXCL10 Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action Year: 2016
Dual role of M2 macrophages in asthma Source: International Congress 2015 – Immune mechanisms in the human lung Year: 2015